POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC

Launched by INSTITUTE OF CANCER RESEARCH, UNITED KINGDOM · Mar 13, 2023

Keywords

ClinConnect Summary

The POTENT clinical trial is exploring the effects of two drugs, tepotinib and pembrolizumab, for patients with advanced non-small cell lung cancer (NSCLC). Pembrolizumab, also known as Keytruda, is already approved for treating various cancers, while tepotinib is being tested for its ability to target specific genetic changes in cancer cells that can lead to uncontrolled growth. This trial specifically aims to help patients whose cancers haven't responded well to other immunotherapy treatments. It will include patients both with and without a particular mutation in the MET gene, which can drive cancer growth.

To be eligible for the trial, participants need to be at least 18 years old and have a confirmed diagnosis of NSCLC. They should either have not received any previous treatment for advanced cancer or have already undergone certain therapies. Participants can expect to be closely monitored throughout the study and will need to provide informed consent. It’s important to know that there are specific health criteria that must be met, including not having recent major surgeries or active infections. This trial represents a promising approach to treating challenging cases of NSCLC, and those interested should discuss their eligibility with their healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • 1. Male or female patients aged 18 or over; 2. Non-small cell lung cancer histologically confirmed; 3.
• Part A:
• • Either
• • a) Exon 14 MET mutation (on tissue or ctDNA testing); b) Patients have not received prior immunotherapy; c) Patients who have received previous MET inhibitor therapy must have PD-L1 TPS≥50% (not required in those naïve to MET inhibitors).
• • Or a) Patient has received at least one line of systemic anticancer therapy for metastatic disease; b) Patient has received at least two cycles of immune checkpoint inhibitor and has demonstrated disease progression within 12 weeks of last dose.
• • 4.
• Part B:
• • Cohort 1
• • a) Exon 14 MET mutation (on tissue or ctDNA testing); b) Patients have not received prior immunotherapy; c) Patients who have received previous MET inhibitor therapy must have PD-L1 TPS≥50% (not required in those naïve to MET inhibitors).
• • 5. Measurable disease as assessed by iRECIST 6. Life expectancy of at least 12 weeks. 7. World Health Organisation (WHO) performance status of 0 or 1(Appendix 1). 8. Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week (Day -7 to Day 1) prior to the patient's first dose of IMP.
• • Haemoglobin (Hb) ≥ 9.0 g/dL Absolute neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x (ULN) unless raised due to tumour in which case up to 5 x ULN is permissible Renal function
• Either:
• • Serum creatinine ≤ 1.5 x upper limit of normal (ULN); Or GFR ≥ 50 mL/min (uncorrected value) Calculated creatinine clearance (using the Wright, Cockcroft \& Gault formula) Coagulation INR \< 1.5 APTT \<1.5x ULN Unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants
• • 9. Written (signed and dated) study informed consent and be capable of co-operating with treatment and follow-up. If patient does not comply with study procedures such that safety of the trial is affected then they will be withdrawn from the study.
• • 10. Female patients with reproductive potential must have a negative urine or serum pregnancy test performed within 7-days prior to start of trial.
• Exclusion Criteria:
• • 1. Endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C) and four weeks for investigational medicinal products), except for bisphosphonates or RANK ligand antagonists that are permitted for the management of bone metastases. Radiotherapy at radical doses within 6 months and at palliative doses within 2 weeks. Patients already receiving tepotinib prior to trial are not required to cease tepotinib prior to trial entry.
• • 2. Ongoing Grade 2 or greater toxicities of previous treatments. Exceptions to this are alopecia and ongoing anticoagulation therapy due to prior thromboembolic episodes.
• • 3. History of ILD or interstitial pneumonitis requiring steroid administration. 4. Ability to become pregnant (or already pregnant or lactating). However, those female patients who have a negative serum or urine pregnancy test before enrolment and agree to use two highly effective forms of contraception (oral, injected or implanted hormonal contraception and condom, have an intra-uterine device and condom) for four weeks before entering the trial, during the trial and for six months afterwards are considered eligible.
• • 5. Male patients with partners of child-bearing potential (unless they agree to take measures not to father children by using a barrier method of contraception \[condom plus spermicide\] or to sexual abstinence effective from the first administration of IMP throughout the trial and for six months afterwards. Men with partners of child-bearing potential must also be willing to ensure that their partner uses an effective method of contraception for the same duration for example, hormonal contraception, intrauterine device, diaphragm with spermicidal gel or sexual abstinence). Men with pregnant or lactating partners must be advised to use barrier method contraception (for example, condom plus spermicidal gel) to prevent exposure of the foetus or neonate.
• • NB. Abstinence is only considered to be an acceptable method of contraception when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
• • 6.
• Known untreated or active central nervous system (CNS) metastases (progressing or requiring corticosteroids for symptomatic control). Patients with a history of treated CNS metastases are eligible, provided they meet all of the following criteria:
• • Evaluable or measurable disease outside the CNS is present.
• • Radiographic stability upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the baseline disease assessment
• • Not requiring corticosteroids. 7. Major surgery within four weeks of the first dose of study treatment. 8. At high medical risk because of non-malignant systemic disease including active uncontrolled infection.
• • Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
• • 10. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to the first dose of trial treatment.
• • 11. Has an active autoimmune disease that has required systemic treatment in past 3 months (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with a history of inflammatory bowel diseases such as Crohn's disease or ulcerative colitis will be excluded from the study. Patients with Sjogren's syndrome will not be excluded from the study. In addition, patients that experienced a Grade 2 or higher immune-related AEs on treatment with immunotherapy will be excluded from the study. Patients with inactive autoimmune disease which has previously required systemic therapy, may be considered on a case-by-case basis after discussion with the chief investigator.
• • 12. Has a known history of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins.
• • 13. Has received a live vaccine within 30 days of planned start of study therapy. Note: The killed virus vaccines used for seasonal influenza vaccines for injection are allowed; however intranasal influenza vaccines (e.g. FluMist®) are live attenuated vaccines and are not allowed.
• • 14. Has experienced hypersensitivity to tepotinib, pembrolizumab or any of their excipients.
• • 15.
• Any of the following cardiac criteria:
• • Mean resting corrected QT interval (QTc) \> 470 msec obtained from 3 consecutive electrocardiograms (ECGs) within 5 minutes of each other. Known congenital QT syndrome or history of torsades de pointes.
• • Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG, e.g. complete left bundle branch block, third degree heart block. Controlled atrial fibrillation is allowed.
• • Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association \[NYHA Grade 2 or above\], severe valvular disease, uncontrolled hypertension despite optimal therapy.
• • Prior bone marrow transplant or have had extensive radiotherapy to greater than 25% of bone marrow within eight weeks.
• • 17. Current malignancies of other types, with the exception of adequately treated cone biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. An exception to this criteria are cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for three years or more and are deemed at negligible risk for recurrence, are eligible for the trial.
• • 18. Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this Phase I study. Participation in an observational trial would be acceptable.
• • 19. Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.
• • 20. Symptoms of active COVID-19 and/or documented active COVID-19 infection at the time of screening.